Dacomitinib, another pan-ERBB inhibitor, had shown extended PFS and overall survival (45), whereas amivantamab, a bispecific antibody targeting EGFR and MET, has shown improved efficacy in combination with lazertinib as a first-line treatment of EGFRm+ NSCLC (46). The gene discussed is MET; the disease is non-small cell lung carcinoma.